| 1 | Factors predicting poor prognosis in ischemic colitis显示文摘瞄准:决定临床、分析、内视镜的因素与有关是化学家大肠炎(IC ) 严厉。方法:85 个病人的一个总数从 1996 年 1 月在回顾的研究被注册到 2004 年 5 月。有 53 女性和 32 男性(年龄 74.6+/-9.4 年,范围 45-89 年) 。病人作为 IC 被诊断。下列变量包括年龄,性别,从到承认的症状的外观的时间的经期,病历,药,凳子频率,临床的症状和症状被分析,验血(血克和基本生物化学的侧面) ,和内视镜的调查结果。病人们在温和 IC 组和严重 IC 组(外科或死亡) 被划分。质的变量用 chi 平方测试被分析,参量的数据用学生的 t (P<0.05 ) 被分析。结果:温和 IC 组 69 个病人被在于(42 女性和 27 男性,平均年龄 74.7+/-12.4 年) 。严重 IC 组由 16 个病人组成(11 女性和 5 男性,平均 73.8+/-12.4 年的年龄) 。因为麦克匪特斯氏疗法(没有外科) 的失败,一个病人死了, 15 个病人经历了外科(6 在内视镜的诊断以后并且 9 在 peroperatory 以后诊断) 。85 个病人(9.6%) 中的八个死了,其它被跟随在上面作为为 9.6+/-3.5 瞬间的门诊病人。人口统计的数据,病历,药和凳子频率在两个组(P>0.05 ) 是类似的。说正经的有病的病人比稍微有病的病人有更少的便血(37.5% 对 86.9% , P = 0.000 ) 。更多的心悸亢进(45.4% 对 10.1% , P = 0.011 ) 并且假腹膜炎的更高的流行签名(75% 对 5.7% , P = 0.000 ) 当腹的疼痛的存在和紧张在二个组之间是类似的时,在严重 IC 组被观察。当承认时,有严重 IC 的二个病人有吃惊。关于分析数据,更严重有病的病人被发现比略微有病的病人有贫血症和血钠过少(37.5% 对 10.1% , P = 0.014 和 46.6% 对 14.9% , P = 0.012,分别地) 。狭窄是那比在稍微有病的病人更经常出现在严重有病的病人的唯一的内视镜的发现(66.6% 对 17.3% , P = 0.017 ) 。结论:能预言 IC 的差的预后是便血,心悸亢进和假腹膜炎,贫血症和血钠过少和狭窄的缺席的因素。 | Ramón A■ón Marta Maia Boscá Vicente Sanchiz Joan Tosca Pedro Almela Cirilo Amorós Adolfo Benages | 2006 | World Journal of Gastroenterology2006，12，30： | 21 |
| 2 | Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study显示文摘AIM To evaluate the real-world effectiveness of golimumab in ulcerative colitis(UC) and to identify predictors of response.METHODS We conducted an observational, prospective and multi-center study in UC patients treated with golimumab, from September 2014 to September 2015. Clinical activity was assessed at wk 0 and 14 with the physician's global clinical assessment(PGA) and the partial Mayo score. Colonoscopies and blood tests were performed, following daily-practice clinical criteria, and the results were recorded in an SPSS database.RESULTS Thirty-three consecutive patients with moderately to severely active UC were included. Among them, 54.5% were female and 42 years was the average age. Thirty percent had left-sided UC(E2) and 70% had extensive UC(E3). All patients had an endoscopic Mayo score of 2 or 3 at baseline. Twenty-seven point three percent were anti-tumor necrosis factor(TNF) treatment na?ve, whereas 72.7% had previously received infliximab and/or adalimumab. Sixty-nine point seven percent showed clinical response and were steroid-free at wk 14(a decrease from baseline in the partial Mayo score of at least 3 points). Based on PGA, the clinical remission and clinical response rates were 24% and 55% respectively. Withdrawal of corticosteroids was observed in 70.8% of steroid-dependent patients at the end of the study. Three out of 10 clinical non-responders needed a colectomy. Mean fecal calprotectin value at baseline was 300 μg/g, and 170.5 μg/g at wk 14. Being anti-TNF treatment na?ve was a protection factor, which was related to better chances of reaching clinical remission. Twenty-seven point three percent of the patients required treatment intensification at 14 wk of followup. Only three adverse effects(AEs) were observed during the study; all were mild and golimumab was not interrupted.CONCLUSION This real-life practice study endorses golimumab's promising results, demonstrating its short-term effectiveness and confirming it as a safe drug during the induction phase. | Marta Maia Bosca-Watts Xavier Cortes Marisa Iborra Jose Maria Huguet Laura Sempere Gloria Garcia Rafa Gil Mari Fe Garcia Marga Munoz Pedro Almela Nuria Maroto Jose Maria Paredes | 2016 | World Journal of Gastroenterology2016，22，47： | 5 |
您所在的机构暂未开通此部分的功能，请联系管理员